FDA Approves Latest GLP-1 Receptor Agonists for Chronic Weight Management

The U.S. Food and Drug Administration (FDA) has issued its latest approvals for GLP-1 receptor agonists, including formulations of semaglutide and liraglutide, specifically indicated for chronic weight management in adults with obesity or overweight conditions. These drugs work by regulating appetite and metabolism.